Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Novo Nordisk Inc News

S&P report emphasizes the concentration risk faced by major pharmaceutical companies during the surge of deals leading up to JPMorgan's conference.

09 Jan, 2026

Research reveals the rapid weight regain following the discontinuation of weight-loss medications - France 24

08 Jan, 2026

Research reveals the rapid weight regain following the discontinuation of weight-loss medications - RFI

08 Jan, 2026

Obesity Therapies Outperform Keytruda, Transforming the Market for Blockbuster Medications

08 Jan, 2026

See More